Oncology Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	FY 2013	FY 2011	FY 2004	FY 2003	FY 2002
Period Ending	Mar '13 Mar 31, 2013	Jun '11 Jun 30, 2011	Mar '04 Mar 31, 2004	Mar '03 Mar 31, 2003	Mar '02 Mar 31, 2002
Net Income	0.19	-	-1.57	-1.52	-1.95
Depreciation & Amortization	0.01	-	0.08	0.4	0.34
Loss (Gain) From Sale of Assets	-	-	-0.14	0	0
Asset Writedown & Restructuring Costs	-	-	-	0.12	-
Other Operating Activities	-	-	-	-0.09	0
Change in Accounts Receivable	-	-	0.15	-0.11	0.29
Change in Inventory	-0.18	-	-	-	-
Change in Accounts Payable	-0.01	-	-0.54	-0.07	-0.32
Change in Unearned Revenue	-	-	-0.08	-0.18	0.11
Change in Other Net Operating Assets	-	-	0.08	0.01	0.08
Operating Cash Flow	0.01	-	-2	-1.44	-1.45
Capital Expenditures	-0.01	-	-0.02	-0.15	-0.32
Sale of Property, Plant & Equipment	-	-	0.13	0	-
Sale (Purchase) of Intangibles	-0.01	-	-	-	-
Other Investing Activities	0.2	-	-	-	-
Investing Cash Flow	0.19	-	0.12	-0.15	-0.32
Short-Term Debt Issued	-	-	0.09	-	-
Long-Term Debt Issued	0.21	-	-	-	-
Total Debt Issued	0.21	-	0.09	-	-
Net Debt Issued (Repaid)	0.21	-	0.09	-	-
Issuance of Common Stock	-	-	0.46	0	0.63
Financing Cash Flow	0.21	-	0.55	0	0.63
Foreign Exchange Rate Adjustments	-	-	-	-	-0
Miscellaneous Cash Flow Adjustments	-0.39	-	-	-	-
Net Cash Flow	0.01	-	-1.34	-1.59	-1.14
Free Cash Flow	0	-	-2.02	-1.59	-1.77
Free Cash Flow Margin	7.25%	-	-170.79%	-48.51%	-48.28%
Cash Income Tax Paid	-	-	0	0	0
Levered Free Cash Flow	-	-	-1.49	-1.12	-1.13
Unlevered Free Cash Flow	-	-	-1.49	-1.12	-1.13
Change in Working Capital	-0.18	-	-0.38	-0.36	0.16

Source: S&P Global Market Intelligence. Standard template. Financial Sources.